Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Alto Neuroscience, Inc. (ANRO) had Stock-Based Compensation of $8.11M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-16.18M |
|
-- |
|
-- |
|
$17.05M |
|
$-17.05M |
|
$0.87M |
|
$-16.18M |
|
$-16.18M |
|
$-16.18M |
|
$-16.18M |
|
$-16.18M |
|
$-16.18M |
|
$-17.05M |
|
$-16.90M |
|
28.85M |
|
28.85M |
|
$-0.46 |
|
$-0.46 |
|
| Balance Sheet Financials | |
$177.72M |
|
$1.87M |
|
$6.97M |
|
$184.69M |
|
$11.32M |
|
$18.40M |
|
$22.22M |
|
$33.55M |
|
$151.14M |
|
$151.14M |
|
$151.14M |
|
31.92M |
|
| Cash Flow Statement Financials | |
$-51.77M |
|
$-0.02M |
|
$60.08M |
|
$168.73M |
|
$176.98M |
|
$8.26M |
|
|
Stock-Based Compensation |
$8.11M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.69 |
|
-- |
|
-- |
|
0.11 |
|
0.13 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-51.79M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-10.71% |
|
-10.71% |
|
-8.76% |
|
-9.54% |
|
$4.73 |
|
$-1.80 |
|
$-1.79 |
|